Free tool
Cell therapy stocks
We cover 44 companies grouped under the Cell therapy theme. The median market value in the group is $194.10M. Across the group, the median move over the past trading day is −1.28%. 52% of the 44 with a 200-day average trade above it. Price change over the past year runs from −81.9% to +132.2% across the middle 80 percent of the group, with a median of −15.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
44 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $20.68 | +8.61% | −3.86% | −40.44% |
| IOVA | Iovance Biotherapeutics, Inc. | $8.08 | +71.91% | +220.63% | +233.88% |
| MESO | Mesoblast Limited | $16.84 | +16.54% | −7.27% | +4.47% |
| VCEL | Vericel Corporation | $42.44 | −9.14% | +19.18% | +18.25% |
| BLFS | BioLife Solutions, Inc. | $37.00 | +15.70% | +54.88% | +45.50% |
| VOR | Vor Biopharma Inc. | $23.67 | +18.35% | +103.35% | −40.82% |
| SANA | Sana Biotechnology, Inc. | $4.16 | +26.44% | −0.72% | +23.44% |
| IMMX | Immix Biopharma, Inc. | $14.07 | +66.71% | +159.12% | +617.86% |
| ALLO | Allogene Therapeutics, Inc. | $2.04 | +22.89% | +51.11% | +75.86% |
| PROK | ProKidney Corp. | $1.74 | +12.99% | −21.97% | −30.12% |
| AUTL | Autolus Therapeutics plc | $2.33 | +60.69% | +24.60% | +48.41% |
| ARTV | Artiva Biotherapeutics, Inc. | $11.77 | +11.78% | +178.25% | +259.94% |
| KYTX | Kyverna Therapeutics, Inc. | $8.61 | +14.95% | −1.82% | +133.33% |
| CABA | Cabaletta Bio, Inc. | $3.25 | +19.05% | +47.06% | +116.67% |
| CAPR | Capricor Therapeutics, Inc. | $9.36 | +42.47% | −66.94% | +49.76% |
| IPSC | Century Therapeutics, Inc. | $2.14 | +4.39% | +115.08% | +315.53% |
| LYEL | Lyell Immunopharma, Inc. | $15.49 | +19.25% | −46.55% | +37.32% |
| CLLS | Cellectis S.A. | $3.42 | +20.42% | −28.75% | +28.09% |
| RNAC | Cartesian Therapeutics, Inc. | $10.19 | +33.20% | +50.74% | −4.09% |
| FATE | Fate Therapeutics, Inc. Common Stock | $2.57 | +10.78% | +159.60% | +129.46% |
| LCTX | Lineage Cell Therapeutics, Inc. | $1.12 | +4.67% | −31.71% | −8.20% |
| NKTX | Nkarta, Inc. | $2.63 | +18.47% | +40.64% | +17.41% |
| MXCT | MaxCyte, Inc. | $1.31 | +24.76% | −15.48% | −6.43% |
| ATRA | Atara Biotherapeutics, Inc. | $9.38 | +20.10% | −47.21% | −24.05% |
| ACET | Adicet Bio, Inc. | $8.95 | +9.15% | +1.47% | −26.01% |
| INKT | MiNK Therapeutics, Inc. | $11.79 | +11.86% | +6.03% | −26.22% |
| TCRX | TScan Therapeutics, Inc. | $0.78 | +0.44% | −23.78% | −58.43% |
| TVGN | Tevogen Inc. | $6.70 | +19.86% | −63.19% | −85.43% |
| CCEL | Cryo-Cell International, Inc. | $4.25 | +25.74% | +23.91% | −3.19% |
| ESLA | Estrella Immunopharma, Inc. | $0.73 | −2.54% | −47.48% | −22.34% |
| LGVN | Longeveron Inc. | $0.70 | +17.02% | +18.60% | −14.44% |
| NCEL | NewcelX Ltd. | $3.38 | −2.87% | +61.72% | −84.77% |
| BCDA | BioCardia, Inc. | $1.19 | +52.56% | −6.30% | −38.66% |
| PLUR | Pluri Inc. | $1.48 | −11.90% | −50.50% | −69.17% |
| SNTI | Senti Biosciences Holdings, Inc. | $0.39 | +1.15% | −64.87% | −75.23% |
| INAB | IN8bio, Inc. | $1.19 | +6.76% | −51.83% | −48.03% |
| GDTC | CytoMed Therapeutics Limited | $1.00 | +10.13% | −28.29% | −50.41% |
| FBLG | FibroBiologics, Inc. | $1.41 | +116.92% | −70.62% | −88.25% |
| CELZ | Creative Medical Technology Holdings, Inc. | $1.19 | +61.60% | −39.59% | −63.27% |
| PMCB | PharmaCyte Biotech, Inc. | $0.54 | −8.39% | −26.76% | −44.28% |
| ERNA | Ernexa Therapeutics Inc. | $4.89 | +35.46% | −83.14% | −85.93% |
| BRTX | BioRestorative Therapies, Inc. | $0.22 | −18.64% | −82.22% | −86.10% |
| MBIO | Mustang Bio, Inc. | $0.56 | −11.25% | −47.66% | −63.40% |
| CRBU | Caribou Biosciences, Inc. | $1.65 | +10.74% | +3.77% | −16.67% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.